CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
temozolomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00687323
NCT00687323Phase 2Completed
CompareCT.gov

Phase II Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) Subjects Unsuitable for Standard Induction Therapy Exhibiting Low MGMT Expression

Merck Sharp & Dohme LLC·interventional·Posted May 30, 2008·Updated Jun 7, 2017

In Brief

A Phase 2 clinical trial evaluating temozolomide for Leukemia, Acute Myeloid and Myelodysplastic Syndrome. Completed, enrolled 47 participants.

Detailed Summary

The primary objective of this study is to evaluate the safety, tolerability, and efficacy of temozolomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) participants who are not candidates for standard induction therapy and exhibit low MGMT expression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Acute Myeloid, Myelodysplastic Syndrome
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 30, 2008
Enrollment StartJul 30, 2007
Primary CompletionMay 9, 2011
Study CompletionDec 23, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.1 years ago

Interventions

temozolomidedrug